Sight SciencesSGHT
About: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Employees: 214
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
471% more call options, than puts
Call options by funds: $468K | Put options by funds: $82K
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
11% more funds holding
Funds holding: 70 [Q2] → 78 (+8) [Q3]
0.04% more ownership
Funds ownership: 34.18% [Q2] → 34.22% (+0.04%) [Q3]
4% less capital invested
Capital invested by funds: $113M [Q2] → $108M (-$5.03M) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Stifel Thomas Stephan 39% 1-year accuracy 7 / 18 met price target | 82%upside $5 | Buy Maintained | 6 Feb 2025 |
UBS Danielle Antalffy 69% 1-year accuracy 9 / 13 met price target | 82%upside $5 | Buy Maintained | 27 Jan 2025 |
Lake Street Frank Takkinen 65% 1-year accuracy 13 / 20 met price target | 9%upside $3 | Hold Maintained | 15 Jan 2025 |
Citigroup Joanne Wuensch 66% 1-year accuracy 31 / 47 met price target | 68%upside $4.60 | Neutral Maintained | 11 Dec 2024 |
Financial journalist opinion









